Kidney Fibrosis Pipeline Review, H2 2015
Summary
Global Markets Directs, Kidney Fibrosis Pipeline Review, H2 2015, provides an overview of the Kidney Fibrosiss therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
The report provides a snapshot of the global therapeutic landscape of Kidney Fibrosis
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Kidney Fibrosis and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Kidney Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Kidney Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Kidney Fibrosis Overview 10
Therapeutics Development 11
Pipeline Products for Kidney Fibrosis - Overview 11
Pipeline Products for Kidney Fibrosis - Comparative Analysis 12
Kidney Fibrosis - Therapeutics under Development by Companies 13
Kidney Fibrosis - Therapeutics under Investigation by Universities/Institutes 15
Kidney Fibrosis - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Kidney Fibrosis - Products under Development by Companies 18
Kidney Fibrosis - Products under Investigation by Universities/Institutes 19
Kidney Fibrosis - Companies Involved in Therapeutics Development 20
AbbVie Inc. 20
Angion Biomedica Corp. 21
Bio-inRen 22
BioLineRx, Ltd. 23
BiOrion Technologies B.V. 24
Cellmid Limited 25
Evotec AG 26
Galectin Therapeutics, Inc. 27
GenKyoTex S.A. 28
GNI Group Ltd. 29
Intercept Pharmaceuticals, Inc. 30
Isarna Therapeutics GmbH 31
Lpath, Inc. 32
MorphoSys AG 33
ProMetic Life Sciences Inc. 34
Raptor Pharmaceuticals Corp. 35
Regulus Therapeutics Inc. 36
SciFluor Life Sciences, LLC 37
Kidney Fibrosis - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Target 39
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
ANG-3070 - Drug Profile Product Description 47
Mechanism of Action 47
R&D Progress 47
ANG-3586 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ANG-4011 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ANG-4021 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
BOT-191 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
BRN-1889 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
CAB-101 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
CGEN-856 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
CT-140 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
cysteamine DR - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Drug to Inhibit Galectin-3 for Fibrosis - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Drugs for Tissue Fibrosis - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
F-351 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
GKT-136901 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
GRMD-02 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ICG-001 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
INT-767 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
ISTH-0047 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
LJ-1888 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Lpathomab - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
MOR-107 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
P-007 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
PBI-4050 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
PBI-4419 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Protein to Activate BMP-7 for Obesity, Osteoarthritis, Kidney Fibrosis and Alport Syndrome - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
SAR-339375 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Small Molecules for Fibrosis - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Small Molecules to Inhibit Cyclophilin D for Obesity and Renal Fibrosis - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Small Molecules to Inhibit SphK2 for Oncology, Kideny Disease, Autoimmune Disorders, Fibrosis and Neurodegenerative Diseases - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
SOL-1 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Synthetic Peptides to Agonize BMP7 Receptor for Renal Fibrosis - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Kidney Fibrosis - Recent Pipeline Updates 92
Kidney Fibrosis - Dormant Projects 113
Kidney Fibrosis - Product Development Milestones 114
Featured News & Press Releases 114
Nov 12, 2015: Regulus Announces Grant of Patent Covering Lead microRNA Therapeutics 114
Nov 09, 2015: ProMetic's PBI-4050 data on renal fibrosis and pancreatic function featured at the American Society of Nephrology's annual meeting 114
Oct 29, 2015: ProMetic's PBI-4050 Cleared to Commence Clinical Trial in Patients With Type 2 Diabetes and Multi-Organ Fibrosis in Europe 115
Oct 05, 2015: Regulus to Present Additional Preclinical Data Supporting RG-012 as a Novel microRNA Therapeutic in Development for Alport Syndrome at ASN's Kidney Week 2015 116
Aug 13, 2015: Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases 117
Oct 14, 2014: Regulus Therapeutics To Present New Preclinical Data on Multiple Programs At 10th Annual Oligonucleotide Therapeutics Society Meeting 118
Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter 118
Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis 119
Nov 01, 2012: Prometic Life Sciences Presents Positive Data On New Anti-fibrotic Drug PBI-4419 At American Society Of Nephrology Annual Meeting 119
Oct 20, 2010: GNI Receives F351 Patent Allowance in Japan 119
Appendix 120
Methodology 120
Coverage 120
Secondary Research 120
Primary Research 120
Expert Panel Validation 120
Contact Us 120
Disclaimer 121
List Of Tables
Number of Products under Development for Kidney Fibrosis, H2 2015 11
Number of Products under Development for Kidney Fibrosis - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 14
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Development, H2 2015 17
Products under Development by Companies, H2 2015 18
Products under Investigation by Universities/Institutes, H2 2015 19
Kidney Fibrosis - Pipeline by AbbVie Inc., H2 2015 20
Kidney Fibrosis - Pipeline by Angion Biomedica Corp., H2 2015 21
Kidney Fibrosis - Pipeline by Bio-inRen, H2 2015 22
Kidney Fibrosis - Pipeline by BioLineRx, Ltd., H2 2015 23
Kidney Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2015 24
Kidney Fibrosis - Pipeline by Cellmid Limited, H2 2015 25
Kidney Fibrosis - Pipeline by Evotec AG, H2 2015 26
Kidney Fibrosis - Pipeline by Galectin Therapeutics, Inc., H2 2015 27
Kidney Fibrosis - Pipeline by GenKyoTex S.A., H2 2015 28
Kidney Fibrosis - Pipeline by GNI Group Ltd., H2 2015 29
Kidney Fibrosis - Pipeline by Intercept Pharmaceuticals, Inc., H2 2015 30
Kidney Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2015 31
Kidney Fibrosis - Pipeline by Lpath, Inc., H2 2015 32
Kidney Fibrosis - Pipeline by MorphoSys AG, H2 2015 33
Kidney Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2015 34
Kidney Fibrosis - Pipeline by Raptor Pharmaceuticals Corp., H2 2015 35
Kidney Fibrosis - Pipeline by Regulus Therapeutics Inc., H2 2015 36
Kidney Fibrosis - Pipeline by SciFluor Life Sciences, LLC, H2 2015 37
Assessment by Monotherapy Products, H2 2015 38
Number of Products by Stage and Target, H2 2015 40
Number of Products by Stage and Mechanism of Action, H2 2015 42
Number of Products by Stage and Route of Administration, H2 2015 44
Number of Products by Stage and Molecule Type, H2 2015 46
Kidney Fibrosis Therapeutics - Recent Pipeline Updates, H2 2015 92
Kidney Fibrosis - Dormant Projects, H2 2015 113
List Of Figures
List of Figures
Number of Products under Development for Kidney Fibrosis, H2 2015 11
Number of Products under Development for Kidney Fibrosis - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 13
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Early Stage Products, H2 2015 17
Assessment by Monotherapy Products, H2 2015 38
Number of Products by Top 10 Targets, H2 2015 39
Number of Products by Stage and Top 10 Targets, H2 2015 39
Number of Products by Top 10 Mechanism of Actions, H2 2015 41
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 41
Number of Products by Routes of Administration, H2 2015 43
Number of Products by Stage and Routes of Administration, H2 2015 43
Number of Products by Top 10 Molecule Types, H2 2015 45
Number of Products by Stage and Top 10 Molecule Types, H2 2015 45
